PMID- 33790972
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210402
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - HPLC-MS and Network Pharmacology Analysis to Reveal Quality Markers of 
      Huo-Xue-Jiang-Tang Yin, a Chinese Herbal Medicine for Type 2 Diabetes Mellitus.
PG  - 1072975
LID - 10.1155/2021/1072975 [doi]
LID - 1072975
AB  - Huo-Xue-Jiang-Tang Yin (HXJTY) is a Chinese medicine formulation, which has been 
      widely used for the treatment of various lipometabolism- and 
      glycometabolism-related diseases in clinics. Currently, HXJTY is mainly 
      prescribed to treat patients with type 2 diabetes mellitus (T2DM), yet its 
      chemical and pharmacologic profiles remain to be elucidated. Here, the potential 
      bioactive compound and action mechanism were investigated using chemical and 
      network pharmacology analysis. A rapid HPLC-MS was employed to identify and 
      quantify the component of HXJTY. On the basis of the identified chemical markers 
      from HXJTY, a network pharmacology study, including target gene prediction and 
      functional enrichment, was applied to screen out the main quality markers of 
      HXJTY and explore its potential mechanism for the treatment of T2DM. The results 
      showed that a total of 22 components were identified and quantified from HXJTY by 
      HPLC-MS. Furthermore, 12 active components such as astragaloside IV, 
      calycosin-7-O-beta-D-glucoside, hydroxysafflor yellow A, and others were proposed as 
      quality markers of HXJTY for treating T2DM based on network pharmacology 
      analysis. In addition, 125 corresponding possible therapeutic target genes of 
      T2DM were obtained. These target genes are mainly related to peptidase activity, 
      hydrolase activity, phosphatase activity, and cofactor binding, suggesting the 
      involvement of PI3K-Akt, MAPK, AGE-RAGE, and Rap1 signaling pathways in 
      HXJTY-treated T2DM. Our results may provide a useful approach to identify 
      potential quality markers and molecular mechanism of HXJTY for treating T2DM.
CI  - Copyright (c) 2021 Qiugu Chen et al.
FAU - Chen, Qiugu
AU  - Chen Q
AD  - Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen 
      Traditional Chinese Medicine Hospital, Shenzhen 518033, China.
FAU - Zhao, Yuan
AU  - Zhao Y
AD  - Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen 
      Traditional Chinese Medicine Hospital, Shenzhen 518033, China.
FAU - Li, Maosheng
AU  - Li M
AD  - The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 
      Shenzhen 518033, China.
FAU - Zheng, Ping
AU  - Zheng P
AD  - Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen 
      Traditional Chinese Medicine Hospital, Shenzhen 518033, China.
FAU - Zhang, Shangbin
AU  - Zhang S
AD  - Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen 
      Traditional Chinese Medicine Hospital, Shenzhen 518033, China.
FAU - Li, Huilin
AU  - Li H
AUID- ORCID: 0000-0002-4888-1025
AD  - The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 
      Shenzhen 518033, China.
AD  - Department of Endocrinology, Shenzhen Traditional Chinese Medicine Hospital, 
      Shenzhen 518033, China.
FAU - Chen, Jianping
AU  - Chen J
AUID- ORCID: 0000-0003-1892-9355
AD  - Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen 
      Traditional Chinese Medicine Hospital, Shenzhen 518033, China.
AD  - The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 
      Shenzhen 518033, China.
LA  - eng
PT  - Journal Article
DEP - 20210315
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7984925
COIS- The authors declare no conflicts of interest.
EDAT- 2021/04/02 06:00
MHDA- 2021/04/02 06:01
PMCR- 2021/03/15
CRDT- 2021/04/01 06:27
PHST- 2020/07/01 00:00 [received]
PHST- 2020/12/23 00:00 [revised]
PHST- 2021/03/05 00:00 [accepted]
PHST- 2021/04/01 06:27 [entrez]
PHST- 2021/04/02 06:00 [pubmed]
PHST- 2021/04/02 06:01 [medline]
PHST- 2021/03/15 00:00 [pmc-release]
AID - 10.1155/2021/1072975 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Mar 15;2021:1072975. doi: 
      10.1155/2021/1072975. eCollection 2021.